All In Biotech

Free tool

FAERS Monitor: Qvar Redihaler

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207921 or its brand name (Qvar Redihaler, Beclomethasone Dipropionate). Reports on generic versions are filed under their own applications.

Reports

2,861

Serious

697

24% of reports

Hospitalization

212

Death reported

37

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective393
  • asthma346
  • dyspnoea324
  • cough265
  • device malfunction255
  • device delivery system issue194
  • device issue178
  • product use in unapproved indication126
  • headache125
  • wrong technique in product usage process112
  • product dose omission issue108
  • fatigue99
  • product substitution issue97
  • covid-1996
  • malaise94

Reports by year received

View as table
YearReports
20131
20161
20171
2018355
2019475
2020349
2021308
2022349
2023282
2024331
2025235
2026174

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,298 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device delivery system issueSignal19452.545.89,685
device malfunctionSignal25526.823.86,298
asthmaSignal34622.620.47,129
device issueSignal17814.612.72,250
product substitution issueSignal9712.410.21,007
coughSignal2657.06.21,361
dyspnoeaSignal3244.23.8811
wrong technique in product usage processSignal1124.13.4258
covid-19Signal964.03.3217
product use in unapproved indicationSignal1263.73.2253
product dose omission issueSignal1082.72.2116
drug ineffectiveSignal3932.22.0271
malaise941.61.320
headache1251.51.219
fatigue990.90.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.